About benralizumab
Interleukin-5 receptor alpha antibody
Used for
- Add-on maintenance treatment for severe eosinophilic asthma.
- Treatment of eosinophilic granulomatosis with polyangiitis in adults.
Usual adult dose
Asthma: 30 mg under the skin every 4 weeks for three doses, then every 8 weeks. EGPA: 30 mg every 4 weeks.
Usual dose in children
Asthma, age 6 years and older: 30 mg under the skin every 4 weeks for three doses, then every 8 weeks. Not established for children under 6.
Common side effects
- Headache
- Sore throat
- Fever
- Injection-site reactions
Important warnings
- Not for sudden asthma attacks or acute breathing problems.
- Do not stop inhaled or oral steroids abruptly.
- Serious allergic reactions can occur, including delayed reactions.
- Treat existing parasitic infections before starting, when possible.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is not known whether benralizumab passes into human milk; discuss potential risks and benefits with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.